Salmeterol/fluticasone propionate via Diskus™ once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids

Clinical Drug Investigation

Volumn 28, Issue 3, 2008, Pages 169-181

  Chuchalin, Alexander ^a,c   Jacques, Loretta ^b   Frith, Lucy ^b  

^a Pulmonology Research Institute   (Russian Federation)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Research Institute of Pulmonology   (Russian Federation)

Author keywords

Anti inflammatories, therapeutic use; Antiasthmatics, therapeutic use; Asthma; Beta 2 adrenergic receptor agonists, therapeutic use; Fluticasone propionate, therapeutic use; Salmeterol fluticasone propionate, therapeutic use

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BONE DENSITY; BRONCHODILATATION; CATARACT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; GLAUCOMA; HEADACHE; HUMAN; INFLUENZA; LARYNX PAIN; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PEAK EXPIRATORY FLOW; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; THRUSH; UPPER RESPIRATORY TRACT INFECTION;

EID: 39049161973     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828030-00004     Document Type: Article

References (40)

1. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996; 9 (4): 636-42
2. Zeiger RS, Baker JW, Kaplan MS, et al. Variability of symptoms in mild persistent asthma: baseline data from the MIAMI study. Respir Med 2004; 98 (9): 898-905
3. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: 2006 [online]. Available from URL: http://www.ginasthma.org/Guidelineitem.asp?.?l1= 2&l2 = 1&intId = 60 [Accessed 2007 Jan 9]
4. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003; 361 (9363): 1071-6
5. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164 (8 Pt 1): 1392-7
6. Azzawi M, Bradley B, Jeffery PK, et al. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis 1990; 142 (6 Pt 1): 1407-13
7. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993; 147 (3): 697-704
8. Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16 (5): 802-7
9. Robertson CF, Rubinfeld AR, Bowes G. Pediatric asthma deaths in Victoria: the mild are at risk. Pediatr Pulmonol 1992; 13 (2): 95-100
10. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161 (2 Pt 1): 527-34
11. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105 (6 Pt 1): 1108-16
12. Aubier M, Pieters WR, Schlosser NJ, et al. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93 (12): 876-84
13. Van den Berg NJ, Ossip MS, Hederos CA, et al. Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Pediatr Pulmonol 2000; 30 (2): 97-105
14. Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 2001; 95 (2): 136-46
15. White M, Scott C, Herrle MR, et al. Salmeterol/fluticasone propionate (42/88?g) HFA-MDI improves asthma control in asthmatics previously treated with short- or long-acting beta2-agonists or inhaled corticosteroids [abstract no. 40]. Ann Allergy Asthma Immunol 2001; 86: 81
16. You-Ning L, Humphries M, Du X, et al. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. Int J Clin Pract 2005; 59 (7): 754-9
17. Balsbaugh TA, Chambers CV, Diamond JJ. Asthma controller medications: what do patients want? J Asthma 1999; 36 (7): 591-6
18. D'Urzo A, Karpel JP, Busse WW, et al. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin 2005; 21 (8): 1281-9
19. ZuWallack R, Adelglass J, Clifford DP, et al. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Chest 2000; 118 (2): 303-12
20. Wolfe J, Rooklin A, Grady J, et al. Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by Diskus device in patients with asthma treated with or without inhaled corticosteroids. J Allergy Clin Immunol 2000; 105 (6 Pt 1): 1153-61
21. Nathan RA, Li JT, Finn A, et al. A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest 2000; 118 (2): 296-302
22. Purucker ME, Rosebraugh CJ, Zhou F, et al. Inhaled fluticasone propionate by Diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day. Chest 2003; 124 (4): 1584-93
23. Bootsma GP, Dekhuijzen PN, Festen J, et al. Sustained protection against distilled water provocation by a single dose of salmeterol in patients with asthma. Eur Respir J 1997; 10 (10): 2230-6
24. Kemp JP, Bierman CW, Cocchetto DM. Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring. Ann Allergy 1993; 70 (4): 316-22
25. Rabe KF, Jorres R, Nowak D, et al. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993; 147 (6 Pt 1): 1436-41
26. Verberne AA, Hop WC, Bos AB, et al. Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children. J Allergy Clin Immunol 1993; 91 (1 Pt 1): 127-34
27. Faurschou P, Engel AM, Haanaes OC. Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies. Allergy 1994; 49 (10): 827-32
28. Global Initiative for Asthma. Global Initiative for Asthma (GINA) pocket guide for asthma management and prevention. Bethesda (MD): National Institutes of Health, National Heart, Lung, and Blood Institute, 1998. Publication no. 95-3659B
29. National Institutes of Health. National Asthma Education and Prevention Program. Expert panel report 3: guidelines on the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health, National Heart, Lung and Blood Institute, 2007
30. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL study. Am J Respir Crit Care Med 2004; 170 (8): 836-44
31. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14 (4): 902-7
32. Hwang I, Toshihiko M. Design issues in non-inferiority/equivalence trials. Drug Information Journal 1999; 33: 1205-18
33. van Noord JA, Hill A, Carrillo Diaz T, et al. Clinical equivalence of a salmeterol/fluticasone propionate combination product (50/500μg) delivered via a chlorofluorocarbon-free metered dose inhaler with the DISKUS in patients with moderate to severe asthma. Clin Drug Invest 2001; 21: 243-55
34. Watson L, Kerstjens HA, Rabe KF, et al. Obtaining optimal control in mild asthma: theory and practice. Fam Pract 2005; 22 (3): 305-10
35. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000; 355 (9213): 1399-403
36. Garbe E, LeLorier J, Boivin JF, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277 (9): 722-7
37. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337 (1): 8-14
38. Daley-Yates PT, Tournant J, Kunka RL. Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma. Clin Pharmacokinet 2000; 39 Suppl. 1: 39-45
39. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153 (5): 1481-8
40. Boonsawat W, Goriachkina L, Jacques L, et al. Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma: a placebo-controlled comparison. Clin Drug Invest 2008; 28: 101-11